Little is known about the efficacy and toxicity of anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The present study aimed to address this question. We identified 2848 patients with newly diagnosed LA-NPC receiving IC between January 2012 and May 2015. The propensity score matching (PSM) method was used to balance various factors and to match patients. Survival outcomes and toxicities between different groups were compared. In total, 596 patients were selected at a 1:3 ratio, with 149 in the IC + CTX/NTZ group and 447 in the IC alone group. The 3-year disease-free survival, overall survival, distant metastasis-free survival and locoregional relapse-free survival rates for IC + CTX/NTZ vs IC alone were 84.3% vs 75.2% (P = .059), 94.0% vs 87.9% (P = .053), 88.0% vs 84.9% (P = .412) and 93.3% vs 88.2% (P = .242). Multivariate analysis established a treatment group (IC vs IC + CTX/NTZ) as a prognostic predictor for DFS (hazard ratio [HR], 1.497; 95% confidence interval [CI], 1.016-2.206; P = .041) and OS (HR, 1.984; 95%, CI, 1.023-3.848; P = .043). Grade 3-4 skin reaction (15.4% vs 0.4%, P < .001) and mucositis (10.1% vs 2.7%, P < .001) were more common in the IC + CTX/NTZ group than that in the IC alone group. Our findings suggested that CTX/NTZ in combination with IC may be a more effective and promising strategy for patients with LA-NPC treated with intensity-modulated radiotherapy.
management of locoregionally advanced NPC (LA-NPC) remains unsatisfactory, with a 5-year overall survival (OS) of 67%-77%. 2 Unfortunately, more than 70% of newly cases were locoregionally advanced disease at initial diagnosis. 3 Currently, concurrent chemoradiation (CCRT) is the main standard care for LA-NPC.
Although local and regional control has improved greatly, the rate of distant metastasis after treatment remains high and is the main source of treatment failure. 4 Therefore, identification of novel and effective therapeutic strategies is urgent and crucial for clinicians.
Epidermal growth factor receptor (EGFR), a transmembrane protein highly expressed in most human epithelial malignancies, 5 is a promising therapeutic target in oncology for its correlation with aggressive phenotype, treatment resistance and poor prognosis. 6, 7 EGFR is also highly expressed in NPC 8 and numerous studies have evaluated the efficacy of anti-EGFR targeted therapy. [9] [10] [11] [12] [13] [14] [15] Cetuximab (CTX) or nimotuzumab (NTZ) (anti-EGFR monoclonal antibodies) concurrent with RT could achieve comparable outcomes compared with standard cisplatin-RT. 12, 14 When combined with CCRT, different results were produced. You et al 13 and Xia et al 11 revealed that CTX/NTZ additional to CCRT was more effective than CCRT alone, while Li et al 10 did not identify any difference. Regardless of the controversial efficacy, CTX/NTZ significantly increased the incidence of acute mucositis and acneiform rash during RT, 10, 12 resulting in poor quality of life or even disruption of RT. It seems that anti-EGFR therapy concurrent with RT may not be the best choice.
Induction chemotherapy (IC), given before RT, has been proven as a promising treatment in LA-NPC for its satisfactory compliance and efficacy in reducing distant metastasis. [16] [17] [18] [19] [20] NTZ in combination with IC may further reduce distant metastasis and improve survival outcomes. However, no relative study to date has been carried out. Given this concern, we initiated this retrospective study to evaluate the efficacy and toxicity of CTX/NTZ in combination with IC for LA-NPC.
| MATERIALS AND METHODS

| Study patient
We identified 14 684 patients with newly diagnosed NPC on the big-data, intelligence database platform (YiduCloud Technology, Beijing, China) at Sun Yat-sen University Cancer Center between January 2012 and May 2015. This intelligence platform has been described in detail previously. 21 Inclusion criteria for this study were as follows: (i) stage III-IVB disease; (ii) age ≥ 18 years; (iii) karnofsky performance score (KPS) ≥ 70; (iv) without prior malignancies; (v) receiving IC followed by CCRT or RT alone; (vi) concurrent chemotherapy, if any, should be single-agent cisplatin; and (vii) receiving intensity-modulated radiotherapy (IMRT).
| Pre-treatment staging workup
Conventional staging workup in our center included physical examination of head and neck, direct nasopharyngoscopy, chest radiography or computed tomography (CT), MRI of head and neck, abdominal sonography, whole-body bone scan and blood profiling.
PET-CT would also be recommended for patients with advanced N (N2-3) category. Magnetic resonance (MR) or CT scans of patients were reviewed separately by 2 radiologists employed at our center with more than 10-years' experience, and any discrepancy was resolved by consensus. Tumor stage was determined according to the 8th edition of the International Union against
Cancer/American Joint Committee on Cancer (UICC/AJCC) manual.
| Treatment
All patients received radical IMRT at our center using the simultaneous integrated boost (SIB) technique as previously described. 18, 22 Briefly, the prescribed radiation doses were: 66-70 Gy at 2.12- 24 The caliper was set at 0.01 to achieve a satisfactory match. Survival outcomes were calculated using the Kaplan-Meier method and compared by log-rank test. The multivariate cox proportional hazards model was used to estimate hazard ratios (HR), 95% confidence intervals (CI) and independent prognostic factors.
| Clinical endpoints and statistical analysis
3 | RESULTS
| Patient baseline characteristics
A flow chart of patient inclusion is presented in Figure 1 . In total, 2848 patients were eligible for our study (Table S1 ). An eventual 596 patients were selected by PSM, with 149 in the IC + CTX/NTZ group and 447 in the IC alone group. Baseline characteristics are summarized in Table 1 . The median age for the whole cohort is 43 years, and the male-to-female ratio is 3.8:1. Host and tumor-related factors were well balanced between the IC plus CTX/NTZ and IC alone groups. Moreover, patients in these 2 groups had similar pre-treatment imaging stage workups (Table S2 ) and chemotherapy intensity (Table S3) .
Among the 149 patients receiving anti-EGFR therapy, 56
(37.6%) received CTX and the remaining 93 (62.4%) patients received NTZ. Detailed information on dose and cycle of CTX/NTZ is shown in Table S4 . More patients in the NTZ arm received 2 cycles than those in the CTX arm (P = .001). 
| Subgroup analysis
We conducted further exploratory analysis according to tumor stage as the multivariate analysis indicated it was an independent prognostic factor. In patients with stage III disease, 284 patients were selected (Table S6 ). Univariate analysis found that the IC + CTX/ NTZ group achieved better 3-year DFS and OS but the difference was not significant ( Figure S1 ). When entered into the multivariate analysis, no significant survival difference between IC + CTX/NTZ and IC alone groups were observed (Table S7) . With regard to the 312 patients selected by PSM (Table S8) , similar results were produced for univariate ( Figure S2 ) and multivariate analyses (Table S9 ).
| Grade 3-4 toxicities
The acute toxicity profile during IC and radiotherapy was evaluated between the 2 groups and is presented in Tables 3 and S10 . Generally, patients in the IC + CTX/NTZ group suffered more grade 3-4 
| DISCUSSION
Advanced disease has always been a difficult issue, not only in relation to NPC management but also in many other cancers because prognosis for this subgroup is poor. Therefore, identification and establishment of a novel and effective treatment is urgent and necessary. As far as we know, our study is the first to evaluate the efficacy and safety of anti-EGFR therapy (CTX or NTZ) in combination with induction chemotherapy in LA-NPC treated by IMRT. We found that additional CTX/NTZ to IC could prolong DFS and OS, but not DMFS and LRRFS. Anti-EGFR therapy-related toxicities of skin and mucositis were also more common in the IC + CTX/NTZ group.
With the wide application of IMRT in NPC, local and regional control has improved greatly and distant metastasis has become the main failure pattern. 4, 25 Although CCRT is effective, it may be not powerful enough to reduce distant metastasis for advanced disease. 26 You et al 13 and Li et al 10 enhanced the treatment intensity during concurrent phase by adding CTX/NTZ to standard concomitant cisplatin. However, the efficacy may be unsatisfactory. At the same time, adverse events significantly increased. Possibly, concurrent administration of anti-EGFR therapy with cisplatin is a feasible strategy, but not the best. Additional cycles of chemotherapy like IC or adjuvant chemotherapy (AC) to CCRT may be a better choice.
Actually, IC followed by CCRT is a preferable treatment modality for its better compliance and excellent efficacy 16, 17, 19 compared with CCRT with AC. In our current study, we provide a new insight in improving survival outcomes by enhancing the treatment during induction phase. By adding CTX/NTZ to IC, DFS and OS were significantly improved, indicating this is a promising treatment modality.
Epidermal growth factor receptor on tumor cells has been established as a factor predicting treatment resistance and poor Antitumor efficacy of CTX in combination with conventional chemotherapy has been proven in various EGFR-expressing malignancies like colorectal cancer, head and neck cancers and recurrent NPC. [27] [28] [29] In recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), CTX combined with fluorouracil-cisplatin chemotherapy achieved significantly better DFS and OS compared with fluorouracil-cisplatin alone when given as the first-line therapy. 30 It seems that CTX adds additional anti-tumor efficacy to previously administered chemotherapy and thereby improved efficacy. 28 Taken this, it's reasonable to speculate that CTX/NTZ adds additional efficacy to induction chemotherapy in NPC. Therefore, CTX/ NTZ in combination with IC could achieve better DFS and OS than IC alone in our study.
With regard to the primary analysis, DFS and OS were significantly improved in IC + CTX/NTZ group while DMFS and LRRFS was not. The significantly improved OS and DFS may originate from combined enhancement of DMFS and LRRFS although DMFS alone or LRRFS alone was not significantly improved. When subgroup analysis was conducted according to tumor stage (III or IV), survival outcomes were not significantly difference between IC + CTX/NTZ and IC alone groups in both subgroups. However, survival curves of DFS and OS in the IC + CTX/NTZ groups were always above the curves in the IC alone group, indicating that IC + CTX/NTZ may still be better than IC alone although the difference was not significant.
A main reason responsible for this is the small sample size which was not statistically powerful to detect the difference. Therefore, future study with larger sample is needed to validate these results.
Overall, grade 3-4 toxic events were more common in the IC + CTX/NTZ group than in the IC alone group, and significant differences mainly occurred in anti-EGFR therapy-related toxicities like skin reactions and mucositis. However, the incidence of severe skin and mucositis in our study was significantly less compared with the results in previous studies. 10, [12] [13] [14] Undoubtedly, CTX/NTZ aggravated radiation-induced skin and oral mucositis. Another reason may be that the total dose used in the induction phase is less than that used in concurrent phase. Notably, personal compliance to CTX and NTZ may produce different survival outcomes or different compliance to concurrent chemotherapy. From these considerations, the appropriate dosage and administration way should be further addressed.
Compared with previous studies focusing on the concurrent phase, our study had 2 advantages. First, patients experienced significantly less anti-EGFR therapy-related severe toxicities during radiotherapy, which could result in better tolerance of chemoradiation.
Second, cycles of CTX/NTZ used during the induction phase are F I G U R E 2 Kaplan-Meier survival curves of disease-free survival, overall survival, distant metastasis-free survival and locoregional relapsefree survival for the 596 patients with stage III-IVB nasopharyngeal carcinoma usually less than that in the concurrent phase. Hence, the cost of anti-EGFR therapy is also less.
However, limitations of this study should also be acknowledged.
Our study is retrospective and the sample size may be small, meaning that potential bias exists. By employing the PSM method to balance various factors varying from pre-treatment staging workup to chemotherapy intensity, we reduced the potential bias as much as we could. 24 Moreover, the follow-up duration may be insufficient.
Therefore, we set DFS as the first endpoint to address this. Notably, the dosage of CTX/NTZ used in our study was less than the standard dosage because we had little published evidence regarding the dosage used concurrently with IC. Undoubtedly, further studies are needed to establish the best regimen and dosage. Furthermore, the cycles of IC were not uniform. In light of previous evidence, we recruited patients receiving at least 2 cycles because 2 cycles were sufficient to achieve therapeutic gain. 22 Importantly, we balanced this factor between the 2 groups.
In summary, CTX/NTZ in combination with IC may be a more effective and promising treatment strategy than IC alone in reducing treatment failure and improving overall survival for patients with LA-NPC in the era of IMRT. Our study provides new insight into the usage of targeted therapy in NPC, although these findings need to be validated in prospective studies.
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